104 related articles for article (PubMed ID: 38719240)
1. Translational PET Imaging of Nectin-4 Expression in Multiple Different Cancers with
Zhang J; Duan X; Chen X; Zhang Z; Sun H; Shou J; Zhao G; Wang J; Ma Y; Yang Y; Tian X; Shen Q; Yu W; He Z; Fan Y; Yang X
J Nucl Med; 2024 May; 65(Suppl 1):12S-18S. PubMed ID: 38719240
[TBL] [Abstract][Full Text] [Related]
2. First-in-Human Study of the Radioligand 68Ga-N188 Targeting Nectin-4 for PET/CT Imaging of Advanced Urothelial Carcinoma.
Duan X; Xia L; Zhang Z; Ren Y; Pomper MG; Rowe SP; Li X; Li N; Zhang N; Zhu H; Yang Z; Sheng X; Yang X
Clin Cancer Res; 2023 Sep; 29(17):3395-3407. PubMed ID: 37093191
[TBL] [Abstract][Full Text] [Related]
3. NECTIN-4 targeted theranostics for urothelial cancer: getting ready for primetime?
Filippi L; Schillaci O
Expert Rev Anticancer Ther; 2024; 24(1-2):1-4. PubMed ID: 37994866
[TBL] [Abstract][Full Text] [Related]
4. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
5. Re: First-in-Human Study of the Radioligand
Klümper N; Eckstein M; Hölzel M; Herrmann K; Hadaschik B; Grünwald V
Eur Urol; 2023 Nov; 84(5):514-515. PubMed ID: 37286457
[No Abstract] [Full Text] [Related]
6. PET Imaging of Nectin-4: A Promising Tool for Personalized/Precision Oncology.
Jiang D; Lan X; Cai W
Clin Cancer Res; 2023 Sep; 29(17):3259-3261. PubMed ID: 37417960
[TBL] [Abstract][Full Text] [Related]
7. Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance.
Klümper N; Ralser DJ; Ellinger J; Roghmann F; Albrecht J; Below E; Alajati A; Sikic D; Breyer J; Bolenz C; Zengerling F; Erben P; Schwamborn K; Wirtz RM; Horn T; Nagy D; Toma M; Kristiansen G; Büttner T; Hahn O; Grünwald V; Darr C; Erne E; Rausch S; Bedke J; Schlack K; Abbas M; Zschäbitz S; Schwab C; Mustea A; Adam P; Manseck A; Wullich B; Ritter M; Hartmann A; Gschwend J; Weichert W; Erlmeier F; Hölzel M; Eckstein M
Clin Cancer Res; 2023 Apr; 29(8):1496-1505. PubMed ID: 36534531
[TBL] [Abstract][Full Text] [Related]
8. PET Imaging of Fibroblast Activation Protein in Various Types of Cancer Using
Pang Y; Zhao L; Meng T; Xu W; Lin Q; Wu H; Zhang J; Chen X; Sun L; Chen H
J Nucl Med; 2023 Mar; 64(3):386-394. PubMed ID: 36215571
[TBL] [Abstract][Full Text] [Related]
9. Management of Dermatologic Events Associated With the Nectin-4-directed Antibody-Drug Conjugate Enfortumab Vedotin.
Lacouture ME; Patel AB; Rosenberg JE; O'Donnell PH
Oncologist; 2022 Mar; 27(3):e223-e232. PubMed ID: 35274723
[TBL] [Abstract][Full Text] [Related]
10. A phase I study of enfortumab vedotin in Japanese patients with locally advanced or metastatic urothelial carcinoma.
Takahashi S; Uemura M; Kimura T; Kawasaki Y; Takamoto A; Yamaguchi A; Melhem-Bertrandt A; Gartner EM; Inoue T; Akazawa R; Kadokura T; Tanikawa T
Invest New Drugs; 2020 Aug; 38(4):1056-1066. PubMed ID: 31444589
[TBL] [Abstract][Full Text] [Related]
11. Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models.
Challita-Eid PM; Satpayev D; Yang P; An Z; Morrison K; Shostak Y; Raitano A; Nadell R; Liu W; Lortie DR; Capo L; Verlinsky A; Leavitt M; Malik F; Aviña H; Guevara CI; Dinh N; Karki S; Anand BS; Pereira DS; Joseph IB; Doñate F; Morrison K; Stover DR
Cancer Res; 2016 May; 76(10):3003-13. PubMed ID: 27013195
[TBL] [Abstract][Full Text] [Related]
12. Scratching the Surface: NECTIN-4 as a Surrogate for Enfortumab Vedotin Resistance.
Aggen DH; Chu CE; Rosenberg JE
Clin Cancer Res; 2023 Apr; 29(8):1377-1380. PubMed ID: 36749325
[TBL] [Abstract][Full Text] [Related]
13. Positron emission tomography and computed tomography with [
Pang Y; Zhao L; Shang Q; Meng T; Zhao L; Feng L; Wang S; Guo P; Wu X; Lin Q; Wu H; Huang W; Sun L; Chen H
Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1322-1337. PubMed ID: 34651226
[TBL] [Abstract][Full Text] [Related]
14. Nectin-4 is widely expressed in head and neck squamous cell carcinoma.
Sanders C; Lau JF; Dietrich D; Strieth S; Brossart P; Kristiansen G
Oncotarget; 2022 Oct; 13():1166-1173. PubMed ID: 36268557
[TBL] [Abstract][Full Text] [Related]
15. Somatostatin receptor imaging with [
Zhao L; Pang Y; Wang Y; Chen J; Zhuang Y; Zhang J; Zhao L; Sun L; Wu H; Chen X; Lin Q; Chen H
Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1360-1373. PubMed ID: 34665275
[TBL] [Abstract][Full Text] [Related]
16. Prospective Comparison of
Lan L; Zhang S; Xu T; Liu H; Wang W; Feng Y; Wang L; Chen Y; Qiu L
Radiology; 2022 Sep; 304(3):648-657. PubMed ID: 35579524
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Diagnostic Efficacy of [
Zhang S; Wang W; Xu T; Ding H; Li Y; Liu H; Huang Y; Liu L; Du T; Zhao Y; Chen Y; Qiu L
Front Oncol; 2022; 12():925100. PubMed ID: 35847877
[TBL] [Abstract][Full Text] [Related]
18. The potential utility of [
Lan L; Liu H; Wang Y; Deng J; Peng D; Feng Y; Wang L; Chen Y; Qiu L
Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):963-979. PubMed ID: 34410435
[TBL] [Abstract][Full Text] [Related]
19. The Added Value of
Gu B; Xu X; Zhang J; Ou X; Xia Z; Guan Q; Hu S; Yang Z; Song S
J Nucl Med; 2022 Jun; 63(6):875-881. PubMed ID: 34593594
[No Abstract] [Full Text] [Related]
20. [
Lin R; Lin Z; Chen Z; Zheng S; Zhang J; Zang J; Miao W
Eur J Nucl Med Mol Imaging; 2022 Jul; 49(8):2960-2971. PubMed ID: 35462566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]